ORKA Stock Analysis: Oruka Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 5.558m USD | 12M Return: 610.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 86.1M
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Oruka Therapeutics (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company headquartered in Menlo Park, California, developing monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead candidates are ORKA-001, an antibody targeting the p19 subunit of IL-23 currently in a Phase 2a PsO trial, and ORKA-002, which targets IL-17A and IL-17F and is in Phase 2 development for PsO, psoriatic arthritis, and related conditions.
The pipeline also includes ORKA-003, directed at an undisclosed pathway, and ORKA-021, a sequential combination regimen pairing ORKA-002 with ORKA-001. As a clinical-stage biotechnology company, Oruka has not yet commercialized a product, meaning its valuation is tied primarily to pipeline progress and the potential for future regulatory approvals in the competitive immunology biologics market.
- ORKA-001 Phase 2a psoriasis data readout approaches
- Competition intensifies from Skyrizi and Taltz in IL-23 market
- Cash runway supports pipeline through key clinical milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 2.44 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.18 > 3% & CFO -90.9m > Net Income -116.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 23.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (55.2m) vs 12m ago 32.37% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 395.2m - Total Current Liabilities 16.6m) / Total Assets 504.5m |
| B: -0.44 (Retained Earnings -221.0m / Total Assets 504.5m) |
| C: -0.26 (EBIT TTM -116.3m / Avg Total Assets 440.8m) |
| D: 27.41 (Book Value of Equity 486.7m / Total Liabilities 17.8m) |
| Altman-Z'' = 30.50 = AAA |
As of August 01, 2026, the stock is trading at USD 96.51 with a total of 749,936 shares traded. Over the past week, the price has changed by +4.72%, over one month by +1.41%, over three months by +41.08% and over the past year by +610.15%.
Current recommended Stop Loss: 84.40 (which is 12.5% or 2.2 ATR below the current price).
Oruka Therapeutics has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy ORKA.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 148.2 | 53.5% |
P/B = 11.4556
Revenue TTM = 0.0 USD
EBIT TTM = -116.3m USD
EBITDA TTM = -116.1m USD
Long Term Debt = 1.13m USD (estimated: total debt 1.81m - short term 680k)
Short Term Debt = 680k USD (from shortTermDebt, last quarter)
Debt = 1.81m USD (from shortLongTermDebtTotal, last quarter) (leases 1.81m already included)
Net Debt = -387.0m USD (calculated: Debt 1.81m - CCE 388.8m)
Enterprise Value = 5.17b USD (5.56b + Debt 1.81m - CCE 388.8m)
Interest Coverage Ratio = unknown (Ebit TTM -116.3m / Interest Expense TTM 0.0)
EV/FCF = -56.71x (Enterprise Value 5.17b / FCF TTM -91.2m)
FCF Yield = -1.76% (FCF TTM -91.2m / Enterprise Value 5.17b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 83.0k) / Revenue TTM)
Tobins Q-Ratio = 10.25 (Enterprise Value 5.17b / Total Assets 504.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 1.81m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -91.8m (EBIT -116.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 23.76 (Total Current Assets 395.2m / Total Current Liabilities 16.6m)
Debt / Equity = 0.00 (Debt 1.81m / totalStockholderEquity, last quarter 486.7m)
Debt / EBITDA = 3.33 (negative EBITDA) (Net Debt -387.0m / EBITDA -116.1m)
Debt / FCF = 4.24 (negative FCF - burning cash) (Net Debt -387.0m / FCF TTM -91.2m)
Total Stockholder Equity = 447.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.37% (Net Income -116.3m / Total Assets 504.5m)
RoE = -25.99% (Net Income TTM -116.3m / Total Stockholder Equity 447.3m)
RoCE = -25.93% (EBIT -116.3m / Capital Employed (Equity 447.3m + L.T.Debt 1.13m))
RoIC = -18.80% (negative operating profit) (NOPAT -91.8m / Invested Capital 488.5m)
WACC = 8.55% (E(5.56b)/V(5.56b) * Re(8.55%) + D(1.81m)/V(5.56b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.14 | Cagr: 493.6%
[DCF] Fair Price = unknown (Cash Flow -91.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.13 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.50 | Chg30d=+0.00% | Revisions=+42% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.51 | Chg30d=+0.00% | Revisions=+58% | Analysts=9
EPS current Year (2026-12-31): EPS=-2.04 | Chg30d=-0.09% | Revisions=-25% | GrowthEPS=-10.2% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.49 | Chg30d=-1.21% | Revisions=-25% | GrowthEPS=-22.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +43% (up=15, down=5)